PD-1 Protein (AA 25-167) (His tag)

Catalog No. ABIN6992382

Product Details

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Protein Type: Recombinant

Biological Activity: Active

Protein Characteristics: AA 25-167

Origin: Rhesus Monkey

Source: HEK-293 Cells

Purification tag / Conjugate: This PD-1 protein is labelled with His tag.

Purpose: Rhesus macaque PD-1 / PDCD1 Protein, His Tag (MALS verified)

Purity: >90 % as determined by SDS-PAGE.

Endotoxin Level: Less than 1.0 EU per μg by the LAL method.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: PBS, pH 7.4

Storage: -20 °C

Target Details

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Alternative Name: PD-1 (PDCD1 Products)

Synonyms: CD279 Protein, PD-1 Protein, PD1 Protein, SLEB2 Protein, hPD-1 Protein, hPD-l Protein, Ly101 Protein, Pdc1 Protein, programmed cell death 1 Protein, PDCD1 Protein, Pdcd1 Protein

Background: Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.

Molecular Weight: 17.9 kDa

NCBI Accession: NP_001107830

Pathways: Cancer Immune Checkpoints